According to filings with the U.S. Securities and Exchange Commission, Aulos Bioscience is raising $20,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Aron Knickerbocker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aulos Bioscience
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients own immune systems towards killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos initial clinical candidate, AU-007, has been designed to harness the power of a patients own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies.

To learn more about Aulos Bioscience, visit http://aulosbio.com/

Contact:
Aron Knickerbocker, President and Chief Executive Officer
415-458-2747

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.